Recently, well-respected industry media “Healthcare Executive Magazine” published the list of the 2023 "Top 100 Chinese Innovative Pharmaceutical Comp...

Recently Chinese leading human resource media company HRoot announced its "2023 HRoot Awards in Greater China". Hansoh Pharma was once again honored w...

Recently, during the 2023 Annual Conference of the Chinese Nephrologist Association (CNA), the "First National Medical Information Publication of Pegm...

Recently, the China National Intellectual Property Administration issued its Decision on the Awarding of the 24th China Patent Award. The invention pa...

Hansoh Pharmaceutical Group Co., Ltd. (03692.HK), a leading biopharmaceutical company，and TiumBio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biophar...

On June 30, Hansoh Pharma's Saint Luolai(Pegmolesatide Injection) ,the global unique once-monthly peptide-based highly specific EPO receptor activator...

On June 18, 2023, the Second Anniversary of the Launch of Hansoh Pharma’s HengMu and Academic Conference with the theme of “Light of Life” was held in...

Recently, the internationally renowned pharmacology journal — Frontiers in Pharmacology — published an online clinical study paper on Fulaimei® (PEG-L...